Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Hemogenyx expands its CAR-T trial to children with relapsed leukemia, based on adult safety data.
Hemogenyx Pharmaceuticals has received approval to expand its Phase I trial of HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia, to include pediatric patients.
The amendment, cleared by MD Anderson’s Institutional Review Board, allows enrollment of children and adolescents based on safety and early efficacy data from adult trials.
The move marks a key step in advancing treatment options for younger patients, for whom therapies remain limited.
The company, based in London with U.S. operations in New York City, plans to provide updates as enrollment progresses in both adult and pediatric groups.
13 Articles
Hemogenyx expande su ensayo CAR-T a niños con leucemia recidivante, basado en datos de seguridad de adultos.